Interestingly, HER2 messenger RNA levels were associated with tumor response and in patients with the highest quartile of HER2 messenger RNA, pCR rates were comparable in both arms, suggesting that this assay may help to identify patients more likely to respond well to combined endocrine and anti-HER2 therapy. Here, ERBB2 is linked to neoplasm.